1801 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. It operates through the following geographical segments: The People's Republic of China (PRC), the United States of America (USA), and Indonesia. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
1801 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company